EMBeD: Measuring Endometrial Blood Flow Using Laser Doppler: Acceptability & Reproducibility

Sponsor
Birmingham Women's and Children's NHS Foundation Trust (Other)
Overall Status
Recruiting
CT.gov ID
NCT04906551
Collaborator
(none)
35
1
12
2.9

Study Details

Study Description

Brief Summary

35 participants will be recruited from a list of patients who are scheduled, as part of their routine NHS care, to have a clinically-indicated outpatient hysteroscopy for assessment of their uterine cavity. The participants will be women from the age of 18 up to the age of 40 who are undergoing hysteroscopy investigation. All participants included in the study require at least one ultrasound scan, within the preceding 5 years, demonstrating the presence of a normal uterine cavity devoid of uterine anomalies such as a septate uterus or intrauterine fibroids (which may affect endometrial blood flow measurements). It is usual for a patients to have an ultrasound assessment prior to hysteroscopy therefore we do not anticipate this requirement limiting the number of eligible participants available.

Condition or Disease Intervention/Treatment Phase
  • Device: laser Doppler

Detailed Description

Patient registry: Recruited patients will be registered on 'Edge', a secure, password-protected, database for study participants.

All the investigators will comply with the requirements of the GDPR 2018 with regards to the storage, processing and disclosure of personal information and will uphold the Act's core principles.

Access to patient-identifiable data will be restricted to the core patient-facing members of the research team at Birmingham Women's and Children's Hospital. The patient-facing members will be the Chief Investigator (ME), the Principal Investigator (JC), and co-investigator (HH).

The study involves depersonalised data and the data will be maintained within secure servers. The Birmingham Women's Hospital Research and Development department will hold an archived copy of the study data.

The Chief Investigator (ME) and the Principal Investigator (JC) will act as data custodians and keep the site file locked away securely with restricted access to study data for 25 years. Only the aforementioned members of the research team will have access to the site file for the purpose of quality control, audit and analysis.

Coded, depersonalised data will be created and used for study documents, in place of participant-identifying information. The participant data within the study and the code linking this data to the individual's true identity and identifiable data will be kept in separate locations using encrypted digital files within password-protected folders and storage media

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
35 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
Measuring Endometrial Blood Flow Using Laser Doppler: Acceptability & Reproducibility
Actual Study Start Date :
Jun 7, 2021
Anticipated Primary Completion Date :
Jun 6, 2022
Anticipated Study Completion Date :
Jun 6, 2022

Outcome Measures

Primary Outcome Measures

  1. The intra-operator variability [1 minute]

    The intra-operator variability of the 3 endometrial blood flow values taken for each participant, by a given operator.

  2. The inter-operator variability [1 minute]

    The inter-operator variability, standard deviation, standard error and the variability of measurements taken between participants.

Secondary Outcome Measures

  1. Participant acceptability [5 minutes]

    Participant acceptability of undergoing laser Doppler measurement of endometrial tissue blood flow

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 40 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Women from the age of 18 up to the age of 40 who have consented to hysteroscopy investigation as part of their standard NHS care.

  • Women who have had an ultrasound scan, within the preceding 5 years, demonstrating a normal uterine cavity with no gross anatomical abnormalities (e.g. uterine septum).

  • Women who have given informed consented to take part in the study

Exclusion Criteria:
  • Inability to tolerate vaginal examinations

  • Women who are pregnant

  • Women who do not have regular menstrual cycles

  • Women who have not given consent to the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 BWC Birmingham United Kingdom B4 6NH

Sponsors and Collaborators

  • Birmingham Women's and Children's NHS Foundation Trust

Investigators

  • Principal Investigator: Mary Eyo, Birmingham Women's NHS Foundation Trust

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mary Eyo, Chief Investigator, Birmingham Women's and Children's NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT04906551
Other Study ID Numbers:
  • 250444
First Posted:
May 28, 2021
Last Update Posted:
Aug 23, 2021
Last Verified:
Aug 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 23, 2021